N-丁基-N-甲基-1,3-丙烷二胺 | 13595-43-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-丁基-N-甲基-1,3-丙烷二胺
• 中文别名: 正丁基-N-甲基-丙烷-1,3-二胺；N-(3-氨基丙基)-正丁基-N-甲胺；3-氨基丙基-丁基-甲基-胺
• 英文名称: N-(3-aminopropyl)-N-butyl-N-methylamine
• 英文别名: N'-butyl-N'-methylpropane-1,3-diamine
• CAS: 13595-43-2
• 化学式: C₈H₂₀N₂
• mdl: MFCD06446872
• 分子量: 144.26
• InChiKey: FOIBZJBVQYLKTC-UHFFFAOYSA-N

物化性质

• 沸点：
  94-98 °C(Press: 47 Torr)
• 密度：
  0.841±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2921290000

文献信息

• [EN] TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'HISTONE MÉTHYLTRANSFÉRASES
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2019036384A1

  公开（公告）日：2019-02-21

  The present disclosure provides tricyclic compounds of formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本公开提供了式（I）的三环化合物，它们是组蛋白甲基转移酶G9a和/或GLP抑制剂，因此可用于治疗通过抑制G9a和/或GLP可治疗的疾病，如癌症和血红蛋白病（例如β地中海贫血和镰刀细胞病）。还提供了含有这类化合物的药物组合物以及制备这类化合物的方法。
• Methods of inhibiting and treating biofilms using glycopeptide antibiotics
  申请人：Neesham-Grenon Eve

  公开号：US10201587B2

  公开（公告）日：2019-02-12

  The present invention is directed to methods of inhibition, delay of formation, treatment, prophylaxis and/or prevention of infections caused by bacteria that exhibit tolerance to antimicrobial agents, including slow growing, stationary-phase and biofilm forming bacteria, through the use of glycopeptide antibiotics, such as oritavancin.

  本发明涉及使用糖肽类抗生素，例如奥利他万星，来抑制、延迟、治疗、预防和/或预防由耐抗微生物菌引起的感染的方法，包括生长缓慢、静止期和生物膜形成菌。
• Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same
  申请人：Fahey Robert C.

  公开号：US20100022509A1

  公开（公告）日：2010-01-28

  The present invention utilizes three families of bacterial enzymes, which play a key role in mycothiol biosynthesis. The three families are bacterial cysteine:glucosaminyl inositol ligases (MshC) with catalytic ligase activity for ligation of glucosaminyl inositol and cysteine, bacterial acetyl-CoA:Cys-GlcN-Ins acetyltransferases (MshD) with catalytic activity for addition of an acetyl group to Cys-GlcN-Ins and bacterial MshA glycosyltransferase with catalytic activity for production of GlcNAc-Ins. The invention provides methods for using the mycothiol biosynthesis ligases, acetyltransferases or glycosyltransferases in drug screening assays to determine compounds that inhibit activity. The invention also provides inhibitors of the production or activity of the enzymes of mycothiol biosynthesis, and use of the inhibitors for treating microbial infection.

  本发明利用三种细菌酶家族，它们在肌硫醇生物合成中起着关键作用。这三个家族是：具有催化配体活性的细菌半胱氨酸：葡萄糖胺酰肌醇连接酶（MshC），用于连接葡萄糖胺酰肌醇和半胱氨酸；具有催化活性的细菌乙酰辅酶A：半胱氨酸-GlcN-Ins乙酰转移酶（MshD），用于向Cys-GlcN-Ins添加乙酰基；以及具有催化活性的细菌MshA糖基转移酶，用于生产GlcNAc-Ins。本发明提供了使用肌硫醇生物合成连接酶、乙酰转移酶或糖基转移酶进行药物筛选测定的方法，以确定抑制活性的化合物。本发明还提供了肌硫醇生物合成酶的产生或活性的抑制剂，并将其用于治疗微生物感染。
• Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy
  申请人：Brown Martin J.

  公开号：US20070191372A1

  公开（公告）日：2007-08-16

  The present invention relates to DNA-targeted 1,2,4-benzotriazine-1,4-dioxides and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及以DNA为靶点的1,2,4-苯并三氮唑-1,4-二氧化物及其相关类似物，其制备方法以及它们作为低氧选择性药物和放射增敏剂在癌症治疗中的使用，可以单独使用或与放射线和/或其他抗癌药物结合使用。
• TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS
  申请人：Page Patrick

  公开号：US20100120749A1

  公开（公告）日：2010-05-13

  The present invention is related to tetrahydroindole derivatives of Formula (I), pharmaceutical composition thereof, methods of preparation thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式（I）的四氢吲哚衍生物，其药物组成物，其制备方法以及它们用于治疗和/或预防与尼克酰胺腺嘌呤二核苷酸磷酸酰化酶（NADPH氧化酶）相关的疾病或症状的用途。